ALK and neuroblastoma: First, a differential sensitivity to lorlatinib was seen among the four ALK-driven NB cell lines (Figure 4A–D), with NB1 showing the highest sensitivity (IC50: 1.9 ± 0.1 nM) (Figure 4D) and CLB-GAR showing the lowest sensitivity (IC50: 118.6 ± 43.8 nM) (Figure 4B).